Recommendations for the prevention of respiratory syncytial virus infections;Recomendaciones para la prevención de la infección por virus respiratorio sincitial

Anales Espanoles de Pediatria

Volumn 52, Issue 4, 2000, Pages 372-374

  Carbonell Estrany, X ^a   Quero Jimenez J ^a  

^a NONE   (Spain)

Author keywords

Bronchiolitis; Hospitalization; Monoclonal antibodies; Palivizumab; Premature; RSV

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB;

ARTICLE; CHRONIC LUNG DISEASE; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; NEWBORN; PREMATURITY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 0009834007     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Respiratory syncycial virus
2. Respiratory syncytial virus: A community problem
3. Institute of Medicine Committee on issues and priorities for new vaccine development prospects for immunising against respiratory syncytial virus
4. Bronquiolitis. Revisión de 153 casos y estudio comparativo del tratamiento con ribavirina
5. Respiratory syncytial virus immune globulin intravenous: Indications for use
6. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
8. Prevention of respiratory syncytial virus infections: Indication for the use of palivizumab and update on the use of RSV-IGIV
9. Guidelines for use of Synagis® (palivizumab), a humanized monoclonal antibody, for prevention of respiratory syncytial virus (RSV) disease in high risk infants: A consensus opinion
10. Prevención de las infecciones por virus respiratorio sincitial en España